

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP05/003265

International filing date: 29 March 2005 (29.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: EP  
Number: 04101306.1  
Filing date: 30 March 2004 (30.03.2004)

Date of receipt at the International Bureau: 24 May 2005 (24.05.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

04101306.1

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

R C van Dijk



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

PCT/EP2005 / 003265

Anmeldung Nr:  
Application no.: 04101306.1  
Demande no:

Anmeldetag:  
Date of filing: 30.03.04  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

F. HOFFMANN-LA ROCHE AG  
124 Grenzacherstrasse  
4070 Basel  
SUISSE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se référer à la description.)

PDK4 as marker for PPARdelta modulation


In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

G01N33/48

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL  
PL PT RO SE SI SK TR LI



PDK4 as Marker for PPARdelta Modulation

Peroxisome Proliferator Activated Receptors (PPARs) are members of the nuclear hormone receptor superfamily. The PPARs are ligand-activated transcription factors that regulate gene expression and control multiple metabolic pathways. Three subtypes have  
5 been described which are PPAR $\alpha$ , PPAR $\delta$  (also known as PPAR $\beta$ ), and PPAR $\gamma$ . PPAR $\delta$  is ubiquitously expressed. PPAR $\alpha$  is predominantly expressed in the liver, kidney and heart. There are at least two major isoforms of PPAR $\gamma$ . PPAR $\gamma$ 1 is expressed in most tissues, and the longer isoform, PPAR $\gamma$ 2 is almost exclusively expressed in adipose tissue. The PPARs modulate a variety of physiological responses including regulation of glucose- and lipid-  
10 homeostasis and metabolism, energy balance, cell differentiation, inflammation and cardiovascular events.

Approximately half of all patients with coronary artery disease have low concentrations of plasma High Density Lipidprotein Cholesterol (HDL-C). The atheroprotective function of HDL was first highlighted almost 25 years ago and stimulated  
15 exploration of the genetic and environmental factors that influence HDL levels. The protective function of HDL comes from its role in a process termed reverse cholesterol transport. HDL mediates the removal of cholesterol from cells in peripheral tissues including those in the atherosclerotic lesions of the arterial wall. HDL then delivers its cholesterol to the liver and sterol-metabolizing organs for conversion to bile and  
20 elimination. Data from the Framingham study showed that HDL-C levels are predictive of coronary artery disease risk independently of LDL-C (Low Density Lipidprotein Cholesterol) levels (Gordon et al., *Am. J. Med.* 1977, 62, 707-714). The estimated age-adjusted prevalence among Americans age 20 and older who have HDL-C of less than 35 mg/dl is 16% (males) and 5.7 % (females). A substantial increase of HDL-C is currently

achieved by treatment with niacin in various formulations. However, the substantial side-effects limit the therapeutic potential of this approach.

As many as 90% of the 14 million diagnosed type 2 diabetic patients in the US are overweight or obese, and a high proportion of type 2 diabetic patients have abnormal concentrations of lipoproteins. The prevalence of total cholesterol > 240 mg/dl is 37% in diabetic men and 44% in women. The respective rates for LDL-C > 160 mg/dl are 31% and 44%, respectively, and for HDL-C < 35 mg/dl 28% and 11%, respectively. Diabetes is a disease in which a patient's ability to control glucose levels in blood is decreased because of partial impairment in response to the action of insulin. Type II diabetes (T2D) is also called non-insulin dependent diabetes mellitus (NIDDM) and afflicts 80-90 % of all diabetic patients in developed countries. In T2D, the pancreatic Islets of Langerhans continue to produce insulin. However, the target organs for insulin action, mainly muscle, liver and adipose tissue, exhibit a profound resistance to insulin stimulation. The body continues to compensate by producing unphysiologically high levels of insulin, which ultimately decreases in later stage of disease, due to exhaustion and failure of pancreatic insulin-producing capacity. Thus T2D is a cardiovascular-metabolic syndrome associated with multiple comorbidities including insulin resistance, dyslipidemia, hypertension, endothelial dysfunction and inflammatory atherosclerosis.

First line treatment for dyslipidemia and diabetes generally involves a low-fat and low-glucose diet, exercise and weight loss. However, compliance can be moderate, and as the disease progresses, treatment of the various metabolic deficiencies becomes necessary with e.g. lipid-modulating agents such as statins and fibrates for dyslipidemia and hypoglycemic drugs, e.g. sulfonylureas or metformin for insulin resistance. A promising new class of drugs has recently been introduced that resensitizes patients to their own insulin (insulin sensitizers), thereby restoring blood glucose and triglyceride levels to normal, and in many cases, obviating or reducing the requirement for exogenous insulin. Pioglitazone (Actos<sup>TM</sup>) and rosiglitazone (Avandia<sup>TM</sup>) belong to the thiazolidinedione (TZD) class of PPAR $\gamma$ -agonists and were the first in their class to be approved for NIDDM in several countries. These compounds; however, suffer from side effects, including rare but severe liver toxicity (as seen with troglitazone). They also increase body weight in patients. Therefore, new, more efficacious drugs with greater safety and lower incidence of side effects are urgently needed. Recent studies provide evidence that agonism of PPAR $\delta$  would result in compounds with enhanced therapeutic potential, i. e. such compounds should improve the lipid profile, with a superior effect on HDL-C rising compared to current treatments and with additional positive effects on normalization of insulin-levels

(Oliver et al; Proc Nat Acad Sci USA 2001; 98: 5306-11). Recent observations also suggest that there is an independent PPAR $\alpha$  mediated effect on insulin-sensitization in addition to its well known role in reducing triglycerides (Guerre-Millo et al; J Biol Chem 2000; 275: 16638-16642). Thus, selective PPAR $\delta$  agonists or PPAR $\delta$  agonists with additional PPAR $\alpha$  activity may show superior therapeutic efficacy without the side-effects such as the weight gain seen with PPAR $\gamma$  agonists.

The present invention relates to a marker for PPARdelta modulation, and methods of diagnosing a disease linked to dysregulation of PPARdelta activity, methods of monitoring the treatment of patients suffering from a disease linked to dysregulation of PPARdelta activity, and methods of identifying compounds which modulate PPARdelta activity.

The gene encoding Pyruvate Dehydrogenase Kinase isoenzyme 4 (PDK4) was identified as direct PPARdelta target gene and this gene may be used as biomarker for PPARdelta. PDK4 is implicated in the metabolic response to fasting.

PDK4 was already described as target gene of PPARalpha (Sugden et al., Diabetes. 2001; 50(12):2729-36). However, the present invention provides that the contribution of PPARdelta on PDK4 gene is at least as large as of PPARalpha in certain tissues and cells. Particularly in muscle cells the PDK4 gene is mainly activated by PPARdelta.

20

The present invention provides the use of PDK4 as marker for detecting or monitoring PPARdelta modulation. Preferably, PDK4 is used as marker for detecting or monitoring PPARdelta modulation in muscle cells.

The term "modulation" as used herein relates to an activation or inhibition of the transcriptional activity of PPARdelta. Thus, PDK4 can serve as marker for modulation of PPARdelta activity.

25

The term "marker" as used herein refers to nucleic acid or polypeptide.

The present invention also pertains to PDK4 as marker for diagnosing a disease involving dysregulation of PPARdelta activity such as for example dyslipidemia, obesity or insulin resistance. Thus, PDK4 can serve as marker detecting for the modulation of PPARdelta activity.

5

The present invention further provides a method of detecting or monitoring the activity of PPARdelta in a host comprising quantifying the expression level of PDK4 mRNA. A representative cDNA of mouse PDK4 is shown in SEQ. ID NO: 1.

In one embodiment of the method hereinbefore described the mRNA expression level of  
10 PDK4 is determined relative to a control.

A host may be an animal, tissue, cells or any other biological system that is capable of RNA transcription including in vitro transcription. Preferably, the animal is a non-human animal. The control may be the level of mRNA expression of PDK4 in a different host.

15 Furthermore, the present invention provides a method of determining whether a test compound modulates PPARdelta activity in a host comprising

- a) exposing the host to the test compound and
- b) quantifying the mRNA expression level of PDK4.

In one embodiment of the method hereinbefore described the mRNA expression level of  
20 PDK4 is determined relative to a control.

A host may be an animal, tissue, cells or any other biological system that is capable of RNA transcription including in vitro transcription. Preferably, the animal is a non-human animal. The control is the level of the mRNA expression of PDK4 in an untreated host, which may be the said host before the treatment or a different host, and/or the said host  
25 after an appropriate period of treatment for normalization to pretreatment levels. In a preferred embodiment of the method hereinbefore described, the compound that modulates PPARdelta activity is either an antagonist or an agonist.



The present invention also provides a method for monitoring treatment of patients suffering from a disease associated with dysregulation of PPARdelta activity such as for example dyslipidemia, obesity or insulin resistance, comprising the steps of:

- 5 a) purifying mRNA from muscle cells isolated from patients treated with a modulator of PPARdelta activity and
- b) measuring the mRNA expression of PDK4.

In one embodiment of the method hereinbefore described the mRNA expression level of PDK4 is determined relative to a control.

10 A host may be an animal, tissue, cells or any other biological system that is capable of RNA transcription including in vitro transcription. Preferably, the animal is a non-human animal. The control is the level of the mRNA expression of PDK4 in an untreated host, which may be the said host before the treatment or a different host, and/or the said host after an appropriate period of treatment for normalization to pretreatment levels.

15 The present invention also pertains to compounds identified by the methods hereinbefore described, and to the use of compounds identified by a method hereinbefore described for the preparation of a medicament for the treatment of a disease involving dysregulation of PPARdelta activity such as for example dyslipidemia, obesity or insulin resistance.

20

Several methods for measuring expression levels of PDK4 mRNA can be used. Methods such as Northern Blotting, and quantitation of the bands by densitometry are well known in the art and may be used, although they may not be sufficiently accurate. Other methods include the use of genechips, microarray analysis, dot blotting or different  
25 quantitative PCR methodologies. Preferably, Taqman or real time quantitative PCR is used. Any part of the transcribed sequence of PDK4 may be used as probe. In a preferred embodiment, mRNA expression levels of PDK4 are determined by real-time quantitative PCR using the forward primer and reverse primer listed in table 2 (SEQ. ID NOs: 4 and 5). Preferably, the mRNA expression level of PDK4 in muscle cells is quantified.

30

The present invention further provides a method of detecting or monitoring the activity of PPARdelta in a host comprising quantifying the expression level of PDK4 protein. SEQ. ID NO: 3 shows the protein sequence of mouse PDK4.

- 5        In one embodiment of the method hereinbefore described the protein expression level of PDK4 is determined relative to a control.

A host may be an animal, tissue, cells or any other biological system that is capable of protein translation including in vitro translation. Preferably, the animal is a non-human animal. The control is the level of the protein expression of PDK4 in a different host.

10

Further to this the present invention provides a method of determining whether a test compound modulates PPARdelta activity in a host comprising

- a) exposing the host to the test compound and
- b) quantifying the protein expression level of PDK4.

- 15        In one embodiment of the method hereinbefore the protein expression level of PDK4 is determined relative to a control.

- A host may be an animal, tissue, cells or any other biological system that is capable of protein translation including in vitro translation. Preferably, the animal is a non-human animal. The control is the level of the protein expression of PDK4 in an untreated host,
- 20        which may be the said host before the treatment or a different host, and/or the said host after an appropriate period of treatment for normalization to pretreatment levels. The host may be treated with a carrier. The carrier may be a solvent in which the compound is dissolved or resuspended. In a preferred embodiment of the method hereinbefore described, the compound that modulates PPARdelta activity is either an antagonist or an
- 25        agonist.

Furthermore, the present invention also provides a method for monitoring treatment of patients suffering from a disease associated with dysregulation of PPARdelta activity such as for example dyslipidemia, obesity or insulin resistance, comprising the steps of:

- a) purifying protein from muscle cells isolated from patients treated with a modulator of PPARdelta activity and
- b) measuring the protein expression of PDK4.

In one embodiment of the method hereinbefore the protein expression level of PDK4 is  
5 determined relative to a control.

A host may be an animal, tissue, cells or any other biological system that is capable of protein translation including in vitro translation. Preferably, the animal is a non-human animal. The control is the level of the protein expression of PDK4 in an untreated host, which may be the said host before the treatment or a different host, and/or the said host  
10 after an appropriate period of treatment for normalization to pretreatment levels.

The present invention also pertains to compounds identified by the methods hereinbefore described, and to the use of compounds identified by a method hereinbefore described for the preparation of a medicament for the treatment of a disease involving  
15 dysregulation of PPARdelta activity such as for example dyslipidemia, obesity or insulin resistance.

Several methods for measuring expression levels of PDK4 protein can be used. These methods include but are not limited to two-dimensional gel separation, mass-  
20 spectrometry, antibody binding techniques (ELISA, western blot) and immunoprecipitation. Preferably, the protein expression level of PDK4 in muscle cells is quantified.

Having now generally described this invention, the same will become better understood by reference to the specific examples, which are included herein for purpose of  
25 illustration only and are not intended to be limiting unless otherwise specified, in connection with the following figures.

Figures

Figure 1: Graphical representation from PDK4 gene expression fold changes induced by PPAR ligands in Table 1 (A 300 $\mu$ M, B 100nM, C 500nM) in C2C12 mouse muscle cells measured by Affymetrix micro-arrays. PDK4: Pyruvate Dehydrogenase Kinase isoenzyme 4  
5 uced Adipose Factor [marker for PPARdelta activity], A: 2-[4-(4-Chlorobenzoyl)-phenoxy]-2-methylpropanoic acid (fenofibric acid) [PPARalpha agonist], B: {2-Methyl-4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-phenoxy}-acetic acid [PPARdelta-alpha co-agonist], C: [rac]-(4-{Cyclopentyl-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-methylsulfanyl}-naphthalen-1-yl)-acetic [PPAR delta agonist].

10 Figure 2: Graphical representation from PDK4 gene expression fold changes induced by PPAR ligands in Table 3 (A 300 $\mu$ M, B 100nM, C 500nM, D 500nM) in C2C12 mouse muscle cells measured by qPCR. PDK4: Pyruvate Dehydrogenase Kinase isoenzyme 4 [marker for PPARdelta activity], A: 2-[4-(4-Chlorobenzoyl)-phenoxy]-2-methylpropanoic acid (fenofibric acid) [PPARalpha agonist], B: {2-Methyl-4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-phenoxy}-acetic acid [PPARdelta-alpha co-agonist], C: [rac]-(4-{Cyclopentyl-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-methylsulfanyl}-naphthalen-1-yl)-acetic [PPARdelta agonist], D: (2-Methyl-4-{Methyl-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethyl]-amino}-phenoxy)-acetic acid [PPAR delta-alpha co-agonist].  
15

### Examples

Commercially available reagents referred to in the examples were used according to manufacturer's instructions unless otherwise indicated.

#### 5 Example 1: Microarray experiment

Cell culture: C2C12 cells (ATCC: CRL1772)

Cells were cultured in DMEM (5 mM glucose) supplemented with 10 % heat-inactivated fetal calf serum (FCS). Complete medium was filtered through 0.2 µm pores before use. Differentiation was performed in 6 well dishes by serum depleting the medium  
10 (DMEM High Glucose, 2% FCS) when cells reach confluency. Cell cultures were then incubated for 5 days at 37°C in a 90%-humidified and 95%-air-5%-CO<sub>2</sub> sterile atmosphere to allow differentiation.

PPAR Ligands were dissolved in 100% DMSO and added to medium to adjust 0.1% (v/v) DMSO final concentration and cells were incubated with ligands for 20 hours under  
15 normal growth conditions. Three replicates were done for each condition.

#### RNA extraction

RNA extraction procedure has been performed with Qiagen QIAshredder and RNeasy kits.

20 Approximately  $1 \times 10^6$  pelleted cells per sample were resuspended in 350 µl guanidine thiocyanate containing RLT. Samples were loaded on a QIAshredder-column and centrifuged at full speed for 2 minutes to homogenize the lysates. After adding 350 µl ethanol to the flow-through for better binding conditions, samples were applied to RNeasy spin. For the first wash step 350 µl RW1 buffer were pipetted into the column. Then 10 µl  
25 DNase solution gently mixed with 70 µl RDD buffer were applied onto the column and incubated for 15 minutes at room temperature to remove genomic DNA. DNase was washed out with 350 µl RW1 buffer. Two purifying wash steps followed by adding 500 µl RPE buffer. RNA was eluted in water and stored at - 70°C.

### cDNA synthesis

cDNA was synthesized using the cDNA synthesis system kit supplied by Roche Diagnostics and following the manufacturer's manual. During the whole synthesis it was  
5 worked on ice.

For the first strand synthesis, 2 µl oligo d(T7)T<sub>24</sub> primer (5'GGCCAGTGAATTGTAATACGACTCACTATAGGGAGGCGG-(T)<sub>24</sub> VN 3', 200 pmol/µl) and redist water were added to up to 20 µg RNA for a final reaction volume of 21 µl. After incubation at 70°C for 10 minutes in a thermal cycler and hybridization of the  
10 primers to the RNA, 2 µl AMV reverse transcriptase and 4 µl dNTP-mix (10 mM) were added. Supplementary 8 µl RT-buffer, 4 µl DTT (0.1 mM) and 1 µl RNase inhibitor were pipeted into the mixture. Following incubation at 42°C dured 60 minutes.

Second strand synthesis reagents were added directly into the first strand reaction tube. The second strand enzyme blend, of which 6.5 µl were applied to the mixture,  
15 contains RNase for inserting nicks into RNA of the DNA/RNA hybrid. This provides 3'OH-primers for DNA polymerase I which is also present in the 2<sup>nd</sup> strand enzyme cocktail as well as E.coli ligase too. Additionally 1.5 µl dNTP-mixture, 30 µl 2<sup>nd</sup> strand buffer and 72 µl redist water were added and mixed gently. The reaction mixture was incubated for 2 hours at 16°C. 20 µl added T4 polymerase ensured that the termini of the  
20 cDNA were blunt after 5 minutes incubation at 16°C. Then samples were treated with RNase to remove RNA template (30 minutes at 37°C) and proteinase K (30 minutes, 37°C).

### Purification of cDNA

25 Purification using the QIAquick PCR purification kit was supplied by Quiagen.

850 µl PB buffer were added to the cDNA reaction tube and mixed. Sample were applied to the QIAquick column and centrifuged for 30 seconds at 13000 rpm. 750 µl PE buffer were added to the column to wash cDNA. An additional centrifugation step at maximum speed followed which completely dried the column. To elute DNA, 50 – 80 µl

EB buffer (10 mM Tris-Cl, pH: 8.5) were added to the center of the membrane and the sample was centrifuged for one minute at 13000 rpm.

The cDNA quality was checked by agarose gel electrophoresis and ethidium bromide staining.

5       Smears from 100 to >10000 bp appeared. The quantity and purity of the synthesized cDNA was determined by measuring the absorbance at 260 nm and 280 nm in a spectrophotometer.

The concentration was calculated as follows:  $c[\mu\text{g/ml}] = A_{260} \cdot 50 \cdot D$ , (50: dsDNA specific factor, D: dilution factor). cDNA has a  $A_{260}/A_{280}$ -ratio of 1.8-2.1

10

#### In vitro Transcription (IVT)

This step was performed using MEGAscript T7 kit from Ambion.

5  $\mu\text{g}$  cDNA from each samples were used as template and mixed with ATP, GTP, CTP, UTP (Ambion) and biotinylated CTP (Bio-11-CTP, ENZO) and UTP (Bio-15-UTP, ENZO). RT was performed by T7 enzyme mix for 4 hours at 37°C. Transcription products  
15 were purified with RNeasy kit from Qiagen following the same procedure as for RNA extraction, without any DNase treatment of the samples.

#### Fragmentation of IVT products

20       15  $\mu\text{g}$  RNA from IVT were fragmented in 200 mM Tris-Acetate, pH 8.1, 500 mM KOAc, 150 mM MgOAc for 35 minutes at 95°C in a small volume (20 to 30  $\mu\text{l}$ ).

Chip Handling (cf DNA Micro-array Protocols V3-200.1. M Wilhelm-Seiler, U Certa)

A pre-treatment solution was first applied on Genechip (6.25  $\mu\text{l}$  Acetylated BSA (20  
25  $\mu\text{g}/\mu\text{l}$ ), 12.5  $\mu\text{l}$  salmon sperm DNA (10  $\mu\text{g}/\mu\text{l}$ ), 125  $\mu\text{l}$  2x MES Hyb buffer, 106.25  $\mu\text{l}$   $\text{H}_2\text{O}$ ). Genechip were incubated for 15 min at 40°C with a rotation of 60 rpm in a rotisserie.

Samples were prepared for hybridization as follows: mix 15 µg fragmented RNA with 2.5 µl control stock mix which contains BioB, BioC, BioD, Cre (internal references), 2.5 µl salmon sperm DNA (10 µg/µl), 6.25 µl Acetylated BSA (20 µg/µl), 125 µl 2x MES-Hyb buffer, 91.25 µl H<sub>2</sub>O. Microarrays were then incubated overnight at 45°C with rotation (60 rpm) in a rotisserie.

Samples were removed and stored at -20°C. Microarrays were washed with 6 SSPE for 5 minutes in the fluidics. Then 230 µl MES-Wash buffer were applied to the chip which was incubated at 45°C for 30 minutes, 60 rpm.

Staining was performed by incubating chips with the following solution for 15 minutes: 125 µl 2x Stain Buffer, 91.25 Acetylated BSA, 2.5 µl Streptavidin (1 mg/ml).

Staining solution was removed, micro-arrays washed with 6x SSPE for 5 minutes in the fluidics Station, and treated with the amplification solution: 125 µl 2x Stain Buffer, 99 µl H<sub>2</sub>O, 1 µl Biotinylated-anti-Streptavidin (500 µg/ml), 25 µl Acetylated BSA (20 µg/µl). Incubation for 30 minutes at 40°C with 60 rpm in the rotisserie. After washing I the fluidics Station with 6x SSPE, micro-arrays were incubated with phycoerytrin solution (125 µl 2x Stain buffer, 91.25 µl H<sub>2</sub>O, 31.25 µl acetylated BSA, 2.5 µl Phycoerytrin (1 mg/ml)) at 40°C, with 60 rpm.

#### Solutions:

- 20 12x MES stock : 70.4 g MES free acid monohydrate, 193.3 g MES sodium salt, adjust pH to 6.6, ad 1000 ml with tridest H<sub>2</sub>O
- 2x MES-Hyb Buffer : 8.3 ml 12x MES stock, 17.7 ml 5M NaCl, 4 ml 0.5M EDTA, 0.1 ml 10% Tween 20, 19.9 ml tridest H<sub>2</sub>O
- MES-Wash Buffer : 83.3 ml 12x MES stock, 5.2 ml 5M NaCl, 1 ml 10% Tween 20, ad 1000 ml with tridest H<sub>2</sub>O
- 25 6x SSPE Tween : 300 ml 20x SSPE, 1 ml 10% Tween 20, ad 1000ml tridest H<sub>2</sub>O
- 2x Stain Buffer : 41.7 ml 12x MES stock, 92.5 ml 5M NaCl, 2.5 ml 10% Tween 20, 113.3 ml tridest H<sub>2</sub>O



Scanning is performed with Affymetrix scanner and results were provided on Gene Chip software from Affymetrix.

## 5 Chip Data Analysis

Data were analyzed using Race A Software (Bioinformatic Roche). Triplicates were used for each condition and comparisons were calculated for each condition referring to the control (untreated cell samples). Several criteria have been taken into account for the analysis of each gene: pValue, Call average, Sum average difference, Change Factor and  
10 dispersion in each condition to get a list of the most statistically relevant genes that were modulated by the studied compounds.

## Results

A novel selective PPAR delta biomarker gene was identified from Affymetrix micro-  
15 array experiments (see Fig.1): PDK4 (Pyruvate Dehydrogenase Isoenzyme 4) (SEQ. ID NO: 2). This marker gene allows to differentiate PPAR alpha from PPAR delta activities.

The tested ligands were a PPARalpha agonist (A: 2-[4-(4-Chlorobenzoyl)-phenoxy]-2-methylpropanoic acid (fenofibric acid)), a PPARdelta agonist (C: [rac]-(4-{Cyclopentyl-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-methylsulfanyl}-naphtalen-1-yloxy)-acetic) and a PPARdelta-alpha co-agonist (B: {2-Methyl-4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-phenoxy}-acetic acid).  
20

As shown in Table 1 and Fig. 1 the response of the identified marker gene PDK4 elicit by the PPARdelta agonist (C) and PPARdelta-alpha co-agonist (B) is larger than the response elicited by the PPARalpha specific ligand (A).

	Symbol	Control	A	B	C
pyruvate dehydrogenase kinase, isoenzyme 4	PDK4	1.00	3.30	5.95	6.06

Table 1: PDK4 gene expression fold changes in C2C12 mouse muscle cells induced by PPAR ligands: A 300  $\mu$ M, B 100 nM, C 500 nM measured by Affymetrix micro-arrays. (A: 2-[4-(4-Chlorobenzoyl)-phenoxy]-2-methylpropanoic acid (fenofibric acid) is a PPARalpha agonist, B: {2-Methyl-4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-phenoxy}-acetic acid is a PPARdelta-alpha co-agonist, C: [rac]-(4-{Cyclopentyl-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-methylsulfanyl}-naphthalen-1-ylloxy)-acetic is a PPARdelta agonist)

#### 10 Example 2: quantitative PCR

The culturing of C2C12 mouse muscle cells, RNA extraction, cDNA synthesis and purifications were performed as described in Example 1.

#### PCR Primer Design

- Primer pairs were designed with the software Primer express 1.0 from PE Applied Biosystems based on mRNA/cDNA sequences from Medline. Criteria for each primer were length between 19 to 21 nucleotides, melting temperature of 60  $^{\circ}$ C  $\pm$  1, G/C content range from 40 to 60% and avoidance of secondary structures as hairpins or primer dimers. Additionally the length of the amplicon was controlled as shorter amplicons amplify more efficiently than longer ones and are more tolerant of reaction conditions (usually ~100 bp).
- Primers were dissolved in DEPC treated water (Ambion) to a 100  $\mu$ M concentrated solution and stored at -20  $^{\circ}$ C.

GENE	ACC	OLIGO NAME	FORWARD PRIMER	SEQ. ID:	OLIGO NAME	REVERSE PRIMER	SEQ. ID:
S12	Y11682	mS12_98F	TGAACCAGATGCACCGCTTAG	6	mS12_416R	TTCTTCTTTTGACGTGGCC	7
PDK4	BC026134	mPDK4-1_1632F	TTCAAGTGTTTCCCGCCAT	4	mPDK4-1_1978R	TCCCAACATGCACAATCCTTG	5

Table 2: Forward and reverse primers of gene S12 (internal reference) and PDK4.

#### qPCR using Corbett RG3000 and ABI 7000

- RT-PCR was performed with the Quantitech SYBR Green kit from Qiagen according to the manufacturer's manual. Each component were added to 96 well plate: 25  $\mu$ l master mix, 0.16  $\mu$ l of each primer (100  $\mu$ M stock solution), 22.7  $\mu$ l H<sub>2</sub>O and 2  $\mu$ l cDNA.

The fluorescent dye SYBR green I binds the minor groove of double stranded DNA and allows measurement of DNA quantity at every cycle. The program consists of three different steps: initial denaturation of template and heat-activation of the Taq DNA polymerase (95°C, 15 min), cycling (95°C denaturation, 60 °C primer-template annealing, 5 72°C elongation, fluorescence acquisition), and final melting (melting curve 55 to 95°C, measurements in 0.5 °C steps). The melting curve allows the discrimination between specific and non-specific amplification products (primer dimers).

#### Relative quantification using real-time PCR

10 The relative quantification is based on the relative expression of the target gene versus a reference gene. The concept of threshold fluorescence, defined as the point where fluorescence rises above the background fluorescence enables accurate and reproducible quantification of gene expression. The cycle number at which threshold fluorescence is reached, is called ct value. A linear relation between ct value and the log of the number of  
15 initial molecules is given during the exponential phase of the amplification reaction. Therefore, quantification is reliable at that stage and will not be affected by any limiting effects of the components. The relative ct value of a target gene compared to the ct value of an internal reference in the control or untreated sample is expressed as  $\Delta ct_{\text{control}} =$   
20  $ct_{\text{reference of control}} - ct_{\text{target of control}}$  and in a treated, unknown sample as  $\Delta ct_{\text{sample}} = ct_{\text{reference of sample}} - ct_{\text{target of sample}}$ .

The theoretical PCR reaction is expressed through the formula  $N = N_0 \cdot 2^n$  (N: number of amplified molecules,  $N_0$ : initial number of molecules, n: number of amplification cycles) where the base 2 represents the optimal efficiency (one doubling every cycle). This equation allows to illustrate differential expression in mRNA copy number  
25 instead of ct values: the exponential value with the theoretical efficiency,  $2^{\Delta ct}$ , is taken.

As internal reference for quantitative studies the ribosomal protein S12 gene expression was used. It is expressed constitutively and at the same level in all samples. Setting of fluorescence threshold is determined by the light cycler software. The obtained ct values (duplicates for one sample, two samples per condition) were exported into  
30 Microsoft Excel and analyzed as described above.

#### Results

The novel selective PPAR delta biomarker gene (SEQ. ID. NO: 2) identified from Affymetrix micro-array experiments (see Fig.1) was confirmed by qPCR (quantitative polymerase chain reaction).

The tested ligands were a PPARalpha agonist (A: 2-[4-(4-Chlorobenzoyl)-phenoxy]-2-methylpropanoic acid (fenofibric acid)), a PPARdelta agonist (C: rac)-(4-{Cyclopentyl-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-methylsulfanyl}-naphtalen-1-yloxy)-acetic) and two PPARdelta-alpha co-agonists (B: {2-Methyl-4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-phenoxy}-acetic acid and D: (2-Methyl-4-{Methyl-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethyl]- amino}-phenoxy)-acetic acid).

As shown in Table 3 and Fig. 2 the response of the marker gene PDK4 elicited by the PPARdelta agonist (C) and PPARdelta-alpha co-agonists (B and D) is larger than the response elicited by the PPARalpha specific ligand (A).

	Symbol	Control	A	B	C	D
pyruvate dehydrogenase kinase, isoenzyme 4	PDK4	1	1.77	11.06	4.99	8.63

Table 3: PDK4 gene expression fold changes in C2C12 mouse muscle cells induced by PPAR ligands in C2C12: A 300  $\mu$ M, B 100 nM, C 500 nM, D 500nM as measured by qPCR. (A: 2-[4-(4-Chlorobenzoyl)-phenoxy]-2-methylpropanoic acid (fenofibric acid) is a PPARalpha agonist, B: {2-Methyl-4-[4-Methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethylsulfanyl]-phenoxy}-acetic acid is a PPARdelta co-agonist, C: [rac]-(4-{Cyclopentyl-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-methylsulfanyl}-naphtalen-1-yloxy)-acetic is a PPARdelta agonist, D: (2-Methyl-4-{Methyl-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethyl]- amino}-phenoxy)-acetic acid is a PPARdelta-alpha co-agonist)

Claims

1. PDK4 as biomarker for determining PPARdelta activity.
2. PDK4 as biomarker for determining PPARdelta activity in muscle.
- 5 3. PDK4 as a marker for diagnosing a disease involving dysregulation of PPARdelta activity.
4. A method of detecting or monitoring the activity of PPARdelta in a host comprising quantifying the mRNA expression level of PDK4.
5. A method according to claim 4 comprising the step of determining the mRNA  
10 expression level of PDK4 relative to a control.
6. A method of determining whether a test compound modulates PPARdelta activity in a host comprising
  - a) exposing the host to the test compound and
  - b) quantifying the mRNA expression level of PDK4.
- 15 7. A method according to claim 6 comprising determining the mRNA expression level of PDK4 relative to a control.
8. A method for monitoring treatment of patients suffering from a disease associated with dysregulation of PPARdelta activity, comprising the steps of
  - a) purifying RNA from muscle cells isolated from patients treated with a modulator  
20 of PPARdelta activity and
  - b) measuring the mRNA expression of PDK4.
9. A method according to claim 8 comprising determining the mRNA expression level of PDK4 relative to a control.
10. Compounds identified by the methods of any one of the claims 4 to 9.
- 25 11. Use of compounds identified by a method of any one of the claims 4 to 9 for the preparation of a medicament for the treatment of a disease involving dysregulation of PPARdelta activity.

12. A method of detecting or monitoring the activity of PPARdelta in a host comprising quantifying the protein expression level of PDK4.
13. A method according to claim 12 comprising the step of determining the protein expression level of PDK4 relative to a control.
- 5 14. A method of determining whether a test compound modulates PPARdelta activity in a host comprising
  - a) exposing the host to the test compound and
  - b) quantifying the protein expression level of PDK4.
- 10 15. A method according to claim 14 comprising determining the protein expression level of PDK4 relative to a control.
16. A method for monitoring treatment of patients suffering from a disease associated with dysregulation of PPARdelta activity, comprising the steps of
  - a) purifying protein from muscle cell isolated from patients treated with a modulator of PPARdelta activity and
  - 15 b) measuring the protein expression of PDK4.
17. A method according to claim 16 comprising determining the protein expression level of PDK4 relative to a control.
18. Compounds identified by a method according to any one of the claims 12 to 17.
19. Use of compounds identified by a method according to any one of the claims 12 to 20 17 for the preparation of a medicament for the treatment of a disease involving dysregulation of PPARdelta activity.
20. Use of PDK4 as biomarker for determining PPARdelta activity.
21. Use of PDK4 as biomarker for determining PPARdelta activity in muscle.
22. Use of PDK4 as a marker for diagnosing a disease involving dysregulation of 25 PPARdelta activity.

Abstract

The present invention relates to the use of PDK4 as biomarker for PPARdelta activity, and to methods of diagnosing a disease linked to dysregulation of PPARdelta activity such as for example dyslipidemia, obesity or insulin resistance, methods of  
5 monitoring the treatment of patients suffering from a disease linked to dysregulation of PPARdelta activity, and methods of identifying compounds which modulate PPARdelta activity.

\*\*\*

Fig. 1







Fig. 2



1070392  
SEQUENCE LISTING

<110> F. Hoffmann-La Roche

<120> PDK4 as Marker for PPAR modulation

<130> 22518

<160> 7

<170> PatentIn version 3.2

<210> 1

<211> 3499

<212> DNA

<213> Mus musculus

<220>

<221> Pyruvate Dehydrogenase Kinase isoenzyme 4 (PDK4)

<222> (1)..(3499)

<223> representative cDNA (complete cds) (BC026134, as of 25.03.2004),  
for gene under UniGene ID Mm 235547

```

<400> 1
ccacgcgtcc gaacccttca cccaggctcg agcaccgagg accctgggac cacaacgcac      60
ttgctccctc tcgaccgcgc tcctgaccgc cagccctcgc caaccctacg gatcctaacc      120
accgccagcc taggtgggag tcaggatgaa ggcagccgcg ttcgtgatgc gcagcgccag      180
ctcgctgagc agcgccagcc tggccccag ggaggctcag ctgttctccc gctacagccc      240
gtccccgctg tccatgaagc agctgctgga ctttggttca gaaaatgcct gtgaaagaac      300
gtcctttgct tttctgcggc aagagctgcc cgtccgcctg gccaatatcc tgaaggagat      360
tgacatcctg cctgaccgct tagtgaacac tccttcggtg cagctggtga agagctggtg      420
tatccagagc ctgatggatt tgggtggagt ccatgagaag agcccagaag accagaaagc      480
cctgtcagag tttgtagaca cgctggtcaa agttcgaaac agacatcata atgtggtccc      540
tacaatggct caaggcatcc tggagtataa agacacctgc acagtggacc ccgttaccaa      600
tcaaaatctt cagtattttt tagaccggtt ttacatgaac cgcatttcta ctcggtgct      660
catgaatcag cacatcctca tattcagtga ctcaaagacg ggaaacccaa gccacattgg      720
aagtatcgac ccaaactgtg atgtggtagc agtagtccaa gatgcctttg agtgtgcaaa      780
gatgctctgc gaccagtatt atctaacatc gccagaatta aacctcacac aagtcaatgg      840
aaaattttcca ggccaaccaa tccacattgt gtacgttctt tcacaccttc accacatgct      900
cttcgaactc ttcaagaatg ccatgagggc cagggtcgag catcaagaaa accgtccttc      960
cttgacccca gtagaggcca ctgtcgtctt gggaaaagaa gaccttaca tcaagatttc      1020
tgaccgagga ggcgggtgtc ctctgaggat tactgaccgc ctctttagtt acacgtactc      1080
cactgctcca acacctgtga tggacaattc ccggaatgcc cctttggctg gttttggtta      1140
tggtttgcca atttctcgtc tctacgcaa gtattttcaa ggagatctga atctctactc      1200
tatgtcaggt tatgggacag acgtatcat ctacttaaag gctttatctt ctgagctctg      1260
agaaaagctc ccagtcttta acaagtcagc cttcaaacat tatcagatga gctccgaagc      1320

```

1070392

t gat gact gg t gt at cccaa gcagggaacc gaagaacctg gcgaaggaga agctggcagt	1380
gt gaagcggga tgacgcctga cattttacgg gatcaaagt ggtctgtggc attgctgctt	1440
cgtgaatgtg tgtggactct agtttccgca aaacaacgca acacaaaacc aagcaagcaa	1500
aacacaaaca cgagtacaaa ccttgacctg atgagggaca gagcttgggt ggatgacccg	1560
ggagaagtca gggcagggct ccaggggata acaggtgtcc tgcttctcct ttggcaatgc	1620
aaaatgactc ctgactgttc caaatactga aaagaagtct gcctctgagt tacagctctt	1680
tctcaacaag tacagagttt gaggcttgca gttgcaacag ctggatgttt ggtggttctt	1740
gctgccagcc aaataaattg gtgtttagt aacattttca gtgtttcccc gccatgcaaa	1800
gcttggcgcc ttgggagaaa tgtgtgtaaa tgtacattgt ataggtatta gtgtgctcta	1860
gaaaggacag gatggaagga atcaaagcac tttatcgagc ttgtggctga gcattgcagc	1920
ctatgtgcaa acccagagga aaagtatctc tgtcaagaca gctccagtat catgcagctt	1980
tttatgtttg cactcaaaaa gccagtgcct tctggctggt gccgaggctt gggtgaaatg	2040
ttaaatatgc actgacctca gaaagtcgag ttcaaaaggg agataaaatt gccaaagtga	2100
tccaaggatt gtgcatgttg ggaaacccat atgagagaaa ggattctcat acttagaact	2160
ttcctatgaa gaaatggtagg taaactttct ctacctagaa gtatggaaa ttccaaggct	2220
atcttaaaaa agatgtgcgt tgtatatttt aactacattc tctacactct aacattaaca	2280
tatctattca aatttgtcta gttgccaatt gtcttcagag tgtgaaaatt taaatccttc	2340
ttgaagtatc tttcgtgaga gtagtatgga agtaaaacgt tctcatatca ggaggatgtc	2400
atttgtgaag catggggaca tcatgaacta gtgatgtgcg tgaggcttgg gaggctgaag	2460
ggtaaggatc agcgggaggc catccatgta ggagagagaa ttaaaacgag gagcgaggga	2520
agcaatggag agagggaagc aagaaaggaa ccagaaggct ggcatcatcc tatttcccac	2580
aggctaaccc aagggatgct ctgtgccttt cctggggagg gaaggggatg aactggtaga	2640
tttgaaagca gtatggcttc ttctgtgggt ctccctctta ctagacaagg tgaaatgata	2700
attcgtgtca aattaatgtg aaattttttt cctgcattgt aatattatga ggccagatc	2760
gcagttgagt ttgaaatttg tatttaattt cacagtgacc tagagctaag gtgctccgg	2820
ttgtggcaat aggagccaca agtattttct ttctttcttt cgttctttct ttctttcttt	2880
ctttctttct ttctttcttt ctctttcttc ttctttcttt ccttctttcc ttctttcttt	2940
ccttctttcc ttctttcttt cctttttctt tctcttctct tcttttcttt tttctgtttc	3000
tttttctttt ttgtcattgt agatgtgttc cttaaaagat cagggcagtg actttcacag	3060
caggactttg actcccacat tgggtgatca cacaaaactg tcagcatttg ggtaatctga	3120
tgtatagttg ttttgttgct gatgtttcca ttgaaatttc agctctgagt ttgtgcacat	3180
gaatacttac ttgtgtttac caaaggtcta aggcatcttg ttacttaacc caaatatcct	3240
gaactgtgcg taaagtaata gagaaaagct ttagggtctc aatagtgtca cctgtgtaaa	3300
tcaaatcaaa atagccttcc ctattattta tgaacctatg ggagacttta aactcttgta	3360
gatagatgct aaatgccag gccacttaaa ctattaatg tgtgaattac atttatgttt	3420

1070392

ttagttttata tgcaaagaat tgtgataatt ttataataaa tttttttatt ataaaaaaaa 3480  
 aaaaaaaaaa aaaaaaaaaa 3499

<210> 2  
 <211> 3449  
 <212> DNA  
 <213> Mus musculus

<220>  
 <221> Pyruvate Dehydrogenase Kinase isoenzyme 4 (PDK4)  
 <222> (1)..(3449)  
 <223> representative cDNA (NM\_013743, as of 25.03.2004)

for gene under UniGene ID Mm.235547

<400> 2  
 gagcaccg gaccctggga ccacaacgca cttgctccct ctgaccgag ctccctgaccc 60  
 gcagccctcg ccaaccctac ggatcctaac caccgccagc ctagggtgggc gtcaggatga 120  
 aggcagcccg cttcgtgatg cgcagcgcca gctcgtgag cagcgccagc ctggtcccca 180  
 gggagggtcga gctgtttctc cgctacagcc cgtccccgt gtccatgaag cagctgctgg 240  
 actttggttc agaaaatgcc tgtgaaagaa cgtcctttgc ttttctgcgg caagagctgc 300  
 ccgtccgct ggccaatatc ctgaaggaga ttgacatcct gcctgaccgc ttagtgaaca 360  
 ctccctcggt gcagctggtg aagagctggt atatccagag cctgatggat ttggtggagt 420  
 tccatgagaa gagcccagaa gaccagaaag ccctgtcaga gttttagtag acgctggtca 480  
 aagttcgaaa cagacatcat aatgtgtcc ctacaatggc tcaaggcatc ctggagtata 540  
 aagacacctg cacagtggac cccgttacca atcaaatct tcagtatttt ttagaccggt 600  
 tttacatgaa ccgcatctct actcggtatgc tcatgaatca gcacatcctc atattcagt 660  
 actcaaagac gggaaaccca agccacattg gaagtatcga cccaaactgt gatgtgtag 720  
 cagtagtcca agatgccttt gagtgtgcaa agatgctctg cgaccagtat tatctaact 780  
 cgccagaatt aaacctcaca caagtcaatg gaaaatttcc aggccaaacca atccacattg 840  
 tgtacgttcc ttcacacctt caccacatgc tcttcgaact cttcaagaat gccatgaggg 900  
 ccacgggtcga gcatcaagaa aaccgtcctt ccttgacccc agtagaggcc actgtcgtct 960  
 tgggaaaaga agaccttaca atcaagattt ctgaccgagg aggcgggtgt cctctgagga 1020  
 ttactgaccg cctctttagt tacacgtact ccactgctcc aacacctgtg atggacaatt 1080  
 cccggaatgc ccttttggtt ggttttggtt atggcttgcc aatttctcgt ctctacgcca 1140  
 agtattttca aggagatctg aatctctact ctatgtcagg ttatgggaca gacgctatca 1200  
 tctacttaaa ggctttatct tctgagtctg tagaaaagct ccagctcttt aacaagtcag 1260  
 ccttcaaaca ttatcagatg agctccgaag ctgatgactg gtgtatccca agcagggaac 1320  
 cgaagaacct ggcaaggag aagctggcag tgtgaagcgg atgacgcctg acattttacg 1380  
 ggatcaaagt gggctctgtg cattgctgct tcgtgaatgt gtgtggactc tagtttccgc 1440  
 aaaacaacgc aacacaaaac caagcaagca aaacacaaac acgagtacaa accttgacct 1500

1070392

gatgagggac agagcttggg tggatgaccc gggagaagtc agggcagggc tccaggggat	1560
aacaggtgtc ctgcttctcc tttggcaatg caaaatgact cctgactgtt ccaaatactg	1620
aaaagaagtc tgcctctgag ttacagctct ttctcaacaa gtacagagtt tgaggcttgc	1680
agttgcaaca gctggatgtt tgggtggttct tgctgccagc caaataaatt ggtgtttagt	1740
gaacattttc agtggtttccc cgccatgcaa agcttggcgc cttgggagaa atgtgtgt aa	1800
atgtacattg tataggtatt agtgtgctct agaaaggaca ggatggaagg aatcaaagca	1860
ctttatcgag cttgtggctg agcattgcag cctatgtgca aaccagagg aaaagtatct	1920
ctgtcaagac agctccagta tcatgcagct ttttatgttt gcactcaaaa agccagtgcc	1980
ttctggctgg tgcgaggct tgggtgaaat gttaaatatg cactgacctc agaaagtcga	2040
gttcaaaagg gagataaaat tgccaaagtg atccaaggat tgtgcatgtt gggaaaccca	2100
tatgagagaa aggtattctca tacttagaac ttctctatga agaaatggtg gtaaaactttc	2160
tctacctaga agtagtggaa atttcaaggt catcttaaaa aagatgtgcg ttgtatattt	2220
taactacatt ctctacactc taacattaac atatctattc aaatttgtct agttgccaat	2280
tgtcttcaga gtgtgaaaat ttaaatcctt cttgaagtat ctttcgtgag agtagtatgg	2340
aagtaaaacg ttctcatatc aggaggatgt catttgtgaa gcatggggac atcatgaact	2400
agtgatgtgc gtgaggcttg ggaggctgaa gggttaaggat cagcgggagg ccatccatgt	2460
aggagagaga attaaaacga ggagcgaggg aagcaatgga gagagggaag caagaaagga	2520
accagaagge tggcatcatc ctatttccca caggctaacc caagggatgc tctgtgcctt	2580
tcctggggag ggaagggggg gaactggtag atttgaaagc agtatggctt cttctgtggg	2640
tctccctctt actagacaag gtgaaatgat aattcgtgtc aaattaatgt gaaatttttt	2700
tcctgcattg taatattatg aggccctgag cgcagttgag ttgaaattt gtatttaatt	2760
tcacagtac cttagagctaa ggtgctccc gtgtgtggcaa taggagccac aagtatttc	2820
tttctttctt tegtctttc tttctttctt tctttctttc tttctttctt tctttctttc	2880
cttctttctt tctttctttc cttctttctt tctttctttc cttctttctt tctttcttt	2940
ttctctttc tttttttctt ttttctgtt ctttttctt ttttgcatg tagatgttgt	3000
ccttaaaaga tcagggcagt gactttcaca gcaggacttt gactcccaca ttggttgatc	3060
acacaaaact gtcagcattt gggtaatctg atgtatagtt gttttgttgc tgatgtttcc	3120
attgaaattt cagctctgag tttgtgcaca tgaatactta cttgtgttta ccaaaggctc	3180
aaggcatttg gttacttaac ccaaataatc tgaactgtgc gtaaagtaat agagaaaagc	3240
tttagggtct caatagtgtc acctgtgtaa atcaaatcaa aatagccttc cctattattt	3300
atgaacccat gggagacttt aaactcttgt agatagatgc taaatgccca ggcccactta	3360
acttattaat gtgtgaatta catttatgtt tttagtttat atgcaaagaa ttgtgataat	3420
tttataataa atatttttat tataatagt	3449

1070392

<211> 412  
<212> PRT  
<213> Mus musculus

<220>  
<221> Pyruvate Dehydrogenase Kinase isoenzyme 4 (PDK4)  
<222> (1)..(412)  
<223> protein sequence (O70571, as of 25.03.2004),  
of gene under UniGene ID Mm 235547

<400> 3

Met Lys Ala Ala Arg Phe Val Met Arg Ser Ala Ser Ser Leu Ser Ser  
1 5 10 15  
Ala Ser Leu Val Pro Arg Glu Val Glu Leu Phe Ser Arg Tyr Ser Pro  
20 25 30  
Ser Pro Leu Ser Met Lys Gln Leu Leu Asp Phe Gly Ser Glu Asn Ala  
35 40 45  
Cys Glu Arg Thr Ser Phe Ala Phe Leu Arg Gln Glu Leu Pro Val Arg  
50 55 60  
Leu Ala Asn Ile Leu Lys Glu Ile Asp Ile Leu Pro Asp Arg Leu Val  
65 70 75 80  
Asn Thr Pro Ser Val Gln Leu Val Lys Ser Trp Tyr Ile Gln Ser Leu  
85 90 95  
Met Asp Leu Val Glu Phe His Glu Lys Ser Pro Glu Asp Gln Lys Ala  
100 105 110  
Leu Ser Glu Phe Val Asp Thr Leu Val Lys Val Arg Asn Arg His His  
115 120 125  
Asn Val Val Pro Thr Met Ala Gln Gly Ile Leu Glu Tyr Lys Asp Thr  
130 135 140  
Cys Thr Val Asp Pro Val Thr Asn Gln Asn Leu Gln Tyr Phe Leu Asp  
145 150 155 160  
Arg Phe Tyr Met Asn Arg Ile Ser Thr Arg Met Leu Met Asn Gln His  
165 170 175  
Ile Leu Ile Phe Ser Asp Ser Lys Thr Gly Asn Pro Ser His Ile Gly  
180 185 190  
Ser Ile Asp Pro Asn Cys Asp Val Val Ala Val Val Gln Asp Ala Phe  
195 200 205  
Glu Cys Ala Lys Met Leu Cys Asp Gln Tyr Tyr Leu Thr Ser Pro Glu  
210 215 220

1070392

Leu Asn Leu Thr Gln Val Asn Gly Lys Phe Pro Gly Gln Pro Ile His  
225 230 235 240

Ile Val Tyr Val Pro Ser His Leu His His Met Leu Phe Glu Leu Phe  
245 250 255

Lys Asn Ala Met Arg Ala Thr Val Glu His Gln Glu Asn Arg Pro Ser  
260 265 270

Leu Thr Pro Val Glu Ala Thr Val Val Leu Gly Lys Glu Asp Leu Thr  
275 280 285

Ile Lys Ile Ser Asp Arg Gly Gly Gly Val Pro Leu Arg Ile Thr Asp  
290 295 300

Arg Leu Phe Ser Tyr Thr Tyr Ser Thr Ala Pro Thr Pro Val Met Asp  
305 310 315 320

Asn Ser Arg Asn Ala Pro Leu Ala Gly Phe Gly Tyr Gly Leu Pro Ile  
325 330 335

Ser Arg Leu Tyr Ala Lys Tyr Phe Gln Gly Asp Leu Asn Leu Tyr Ser  
340 345 350

Met Ser Gly Tyr Gly Thr Asp Ala Ile Ile Tyr Leu Lys Ala Leu Ser  
355 360 365

Ser Glu Ser Val Glu Lys Leu Pro Val Phe Asn Lys Ser Ala Phe Lys  
370 375 380

His Tyr Gln Met Ser Ser Glu Ala Asp Asp Trp Cys Ile Pro Ser Arg  
385 390 395 400

Glu Pro Lys Asn Leu Ala Lys Glu Lys Leu Ala Val  
405 410

<210> 4  
<211> 19  
<212> DNA  
<213> Mus musculus

<220>  
<221> PDK4 forward primer  
<222> (1)..(19)

<400> 4  
ttcagtgttt ccccgccat

19

<210> 5  
<211> 21  
<212> DNA  
<213> Mus musculus

1070392

<220>  
<221> PDK4 reverse primer  
<222> (1)..(21)

<400> 5  
tcccaacatg cacaatcctt g

21

<210> 6  
<211> 21  
<212> DNA  
<213> Mus musculus

<220>  
<221> S12 forward primer  
<222> (1)..(21)

<400> 6  
tgaaccagat gcaccgttta g

21

<210> 7  
<211> 20  
<212> DNA  
<213> Mus musculus

<220>  
<221> S12 reverse primer  
<222> (1)..(20)

<400> 7  
ttcttctttt gcacgtggcc

20